46 results about "Motor symptoms" patented technology

Disclosed embodiments include an apparatus for generating a plurality of movement impairment indices from one or more kinematic signals to characterize movement disorders. Additionally we disclose methods for generating a plurality of movement impairment indices from one or more kinematic signals obtained from one or more kinematic sensors, said methods implemented in a digital computer with one or more processors in order to characterize movement disorders based on spectral analysis, regularity metrics, and time-frequency analsysis.

Disclosed embodiments include an apparatus for generating a plurality of movement impairment indices from one or more kinematic signals to characterize movement disorders. Additionally we disclose methods for generating a plurality of movement impairment indices from one or more kinematic signals obtained from one or more kinematic sensors, said methods implemented in a digital computer with one or more processors in order to characterize movement disorders based on spectral analysis, regularity metrics, and time-frequency analysis.

A state of progression in an individual of a disease or treatment having motion symptoms is determined. A time series of accelerometer data is obtained from an accelerometer worn on an extremity of the person, over an extended period during everyday activities of the person. The accelerometer data is processed to produce a plurality of measures of kinetic state of the individual at a respective plurality of times throughout the extended period, each measure of kinetic state comprising at least one of: a measure for bradykinesia, and a measure for dyskinesia. A measure of dispersion of the measures of kinetic state is determined. An output is generated, indicating that motion symptoms are at an initial stage if the measure of dispersion is less than a threshold, or indicating that motion symptoms are at an advanced stage if the measure of dispersion is greater than the threshold.

A gait disorder support apparatus and gait disorder support method capable of detecting an onset sign of a gait disorder associated with motor symptoms in advance and performing motion assist are proposed. The onset sign of the gait disorder associated with the motor symptoms of a wearer is detected based on the correlation between a gait cycle and a reduction ratio of the gait cycle as compared to immediately preceding gait; and when the onset sign of the gait disorder is detected, a drive unit is controlled so that the drive unit applies assist power to a knee joint of the wearer; and on the other hand, when the onset sign of the gait disorder is not detected, the drive unit is controlled so that driving torque by the drive unit does not hinder the wearer's gait motion.

The invention provides a Parkinson's disease auxiliary identification method for constructing brain network modeling based on fMRI and DTI. The method comprises the steps: extracting an fMRI image ofthe brain of a user, and preprocessing the fMRI image; performing calculating based on the region of interest to obtain an fMRI function connection matrix, and identifying brain function connection related to PD motion symptoms; extracting a DTI image of the brain of the user, preprocessing the DTI image, and then performing calculating based on the region of interest to obtain a DTI probability fiber connection matrix; preprocessing the fMRI image and preprocessing the DTI image respectively; identifying brain function connection and probability fiber connection with high representativeness in the fMRI function connection matrix and the DTI probability fiber connection matrix; performing machine learning on the brain function connection and the probability fiber connection with high characterization to obtain PD related connection characteristics, and obtaining characterization parameters most similar to the brain region of a PD patient through the high characterization connection characteristics of the fMRI function connection matrix and the DTI probability connection matrix so as to compare and judge the state of the PD patient.

A method for treating a symptom of a neurodegenerative condition. The method includes topically administering a composition that contains a sex steroid or a cannabinoid or a mixture of both to the forehead, to an area of the outer ear of the subject not including the ear canal, or to both of these anatomical locations. The symptom treatable by the method is a motor symptom or a non-motor symptom.

A method of treating a subject for Parkinson's disease comprises administering said subject a phenylisopropylamine in an amount effective to treat said Parkinson's disease. In some embodiments the method is used to treat at least a motor symptom of Parkinson's disease; in some embodiments the method is used to treat at least a non-motor symptom of Parkinson's disease.

This invention refers to a device that reduces and counteracts human motor symptoms (tremor in the upper limbs, muscular stiffness, bradykinesia or slowness in movements, postural disruptions, Parkinsonian walking and freezing in the walking) caused by Parkinson's disease. The device produces vibration by means of a micro-motor that can be modulated in time, speed and power. A laser diode generates a light that is projected in the ground in the form of a horizontal line, a Bluetooth module communicates this device with different intelligent electronic devices and with applications. These components are powered by a rechargeable handheld power source. The components are powered by a rechargeable handheld electric energy source.

The invention relates to a Parkinson's disease biomarker and application thereof, and belongs to the technical field of medical diagnosis. The biomarker comprises the methylation degree of at least one gene locus in the genes of GPR183, WDR46, PFDN6, SGCE, PEG10, EMX2OS, NFATC4, GJB1, IGF1R, UBAC2, ICA1L, ACRC, PAX6, ALX4, HIST1H4C, HSPA1L, LOC645323, BCYRN1, IGF2BP3, ZNF808, OTUD6A, NELL2, TAF1, EMX2, ARHGAP6, and RALYL. Only the methylation site of the Parkinson's disease biomarker needs to be directionally detected, the experimental method and the judgment method can be standardized, and misdiagnosis caused by human subjective deviation is avoided. Moreover, the Parkinson's disease biomarker can be detected from biological samples such as peripheral blood before the motor symptom of a patient attacks, so that the aim of early diagnosis can be fulfilled.

The invention provides a Parkinson's disease non-motor symptom monitoring platform and application thereof, and belongs to the technical field of online medical treatment. The monitoring platform comprises a patient module, a doctor module and an information processing module. A patient completes a Parkinson's disease non-motor symptom visualization scale on time to assist a doctor in diagnosis and disease course monitoring, and information interaction is realized in the form of an app, a web page or a WeChat applet. The monitoring platform does not occupy the time of clinical communication, and a patient can complete the evaluation on the terminal by himself / herself. When a doctor sees a doctor every time, by calling patient information and an analysis result, the burden rating of the non-motor symptoms can be quantified, the current situation and progress of the non-motor symptoms of the patient can be quickly and accurately mastered, and diagnosis can be timely and accurately carried out.

The present invention relates to methods of treating and managing Parkinson's disease and related disorders. The methods especially find use in managing motor symptoms, including gait problems, particularly during advanced stages when effectiveness of standard medications wear off or side effects become problematic, as seen in Parkinson's disease, other disorders treated with dopaminergic agents, and other conditions associated with motor problems, such as aging or stroke. The treatment also may include disease-modifying effects, neuroprotection of, or neurorescue effects on neuronal cells in patients with Parkinson's disease and other neurodegenerative disorders. In particular, the invention relates to method of administering pharmaceutical compositions comprising effective amounts of tapentadol or a pharmaceutically acceptable salt or derivative thereof or, in other embodiments, stavudine or nabumetone, or a derivative thereof, for treating symptoms associated with Parkinson's disease, either as individual active agents, in combination with each other, or in combination with agents known to treat Parkinson's disease, such as the dopaminergic agent levodopa. The invention also relates to methods of preparing pharmaceutical compositions comprising effective amounts of tapentadol, stavudine, or nabumetone, or a derivative thereof, or further in combination with a dopaminergic agent, or derivative thereof, as well as to methods of using the pharmaceutical compositions in treating Parkinson's disease, related disorders, other conditions treated with dopaminergic agents, and other conditions with gait problems, for example by oral administration of the compositions.

The invention discloses a probiotic composition for treating rapid eye movement sleep behavior disorder (RBD) in patients with Parkinson disease (PD). The composition is prepared from bacillus licheniformis, bifidobacterium longum, lactobacillus acidophilus, enterococcus faecalis and pharmaceutically acceptable auxiliary materials, wherein the number of live bacteria of the bacillus licheniformisis not less than 10.0x10<8> CFU / g; the number of live bacteria of the bifidobacterium longum is not less than 4.0x10<8> CFU / g; the number of live bacteria of the lactobacillus acidophilus is not lessthan 1.0x10<8> CFU / g; and the number of live bacteria of the enterococcus faecalis is not less than 0.5x10<8> CFU / g. In the probiotic composition, the components have a synergistic effect, the RBD symptom in the PD patients can be effectively treated and improved, and the treatment effect is good in continuity and excellent in stability; the composition can effectively improve the motor symptom ofthe PD patients while having a treatment effect on the RBD symptom of the PD patients, and solves the problem that current drugs cannot treat the motor symptom and non-motor symptoms of the PD patients at the same time; and the composition can effectively reduce the dosage of levodopa in the PD patients and prevent the patients from generating resistance to levodopa prematurely, and has a betterprotection effect on the patients.

A method of treating a subject for Parkinson's disease comprises administering said subject a phenylisopropylamine in an amount effective to treat said Parkinson's disease. In some embodiments the method is used to treat at least a motor symptom of Parkinson's disease; in some embodiments the method is used to treat at least a non-motor symptom of Parkinson's disease.

Applications of a Xinnaoxin capsule in preparation of medicines treating Parkinson's disease are disclosed. The applications prove that: the Xinnaoxin capsule obviously improves behaviors of mouse with the Parkinson's disease, obviously increases the contents of DA and HVA in model mice corpus striatum and obviously enhances TH positive expression in the substantia nigra. Each dosage group of the Xinnaoxin capsule obviously improves movement symptoms of the mouse with the Parkinson's disease and effectively increases the contents of dopamine and metabolites of the dopamine in the brain corpus striatum.

A method for treating a symptom of a neurodegenerative condition. The method includes topically administering a composition that contains a sex steroid or a cannabinoid or a mixture of both to the forehead, to an area of the outer ear of the subject not including the ear canal, or to both of these anatomical locations. The symptom treatable by the method is a motor symptom or a non-motor symptom.

An embodiment in accordance with the present invention is directed to a system and device for applying electrical direct current transcranially to the brain that is combined with a behavioral activity consisting of an isometric force production task. The device is non-invasive or implantable and serves to improve motor symptoms in Parkinson's disease (PD) and other movement disorders. During the stimulation, the patient is engaged in a behavioral task using a system consisting of two force transducers and a controller. The patient holds the transducers, one in each hand, and is engaged in a task that requires the brain to assign forces to each arm so that the sum of the forces matches an instructed amount. In an electrode placement specifically for PD, bilateral primary motor cortices are simultaneously stimulated according to a specific algorithm that depends on the forces that the PD affected individual produces in the behavioral task.

The present invention relates to diagnostic methods and kits for the detection and / or diagnosis of at least one synucleinopathy in a subject. More particularly, the invention provides the use of a-Syn and its post translational modifications, specifically, serine 129 phosphorylated a-Syn, as diagnostic markers for Parkinson's disease specifically, for the diagnosis of PD with motor symptoms (PD-M).

Disclosed is a method of treating Parkinson's disease and / or depression, and motor symptoms, non motor symptoms and depression symptoms associated with Parkinson's disease in a subject in need thereof, the method including administering to said subject a pharmaceutical composition comprising rasagiline or a pharmaceutically acceptable salt thereof, wherein the administering is effected by intranasal administration, and wherein a daily dose of the rasagiline or pharmaceutically acceptable salt thereof in the pharmaceutical composition is sufficient to inhibit monoamine oxidase (MAO)-A and MAO-B in a brain but insufficient to inhibit systemic MAO-A and therefore does not potentiate sympathetic cardiovascular activity associated with tyramine rich food consuming. Also, disclosed is a pharmaceutical composition including rasagiline or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, and a device configured for intranasal administration of a pharmaceutical composition including rasagiline or a pharmaceutically acceptable salt thereof to a subject.

The present invention refers to a method, and a related device, which determines a kinetic state of a subject and includes the following operations: the determination of a signal indicative of the acceleration trend (ax, ay, az) on the three Cartesian axes (X, Y, Z); the signal processing to limit the frequency band and preferably reduce artifacts and compensate the offset of the output signals from the multi-axial measurement system; the frequency analysis and spectral analysis through the transformation of the signal with the Fournier transform; the computation of the power spectral density(E) for each axis (Sx, Sy, Sz); and in which a comparison is made between said power spectral density (E) with a characteristic pattern of a movement.

This invention refers to a device that reduces and counteracts human motor symptoms (tremor in the upper limbs, muscular stiffness, bradykinesia or slowness in movements, postural disruptions, Parkinsonian walking and freezing in the walking) caused by Parkinson's disease. The device produces vibration by means of a micro-motor that can be modulated in time, speed and power. A laser diode generates a light that is projected in the ground in the form of a horizontal line, a Bluetooth module communicates this device with different intelligent electronic devices and with applications. These components are powered by a rechargeable handheld power source. The components are powered by a rechargeable handheld electric energy source.

The invention relates to a Parkinson's motion symptom quantitative evaluation method based on a wearable sensing device. The method comprises the steps of initializing a sensor, obtaining original data of multiple typical motion symptoms of the Parkinson's patient, preprocessing the original data, extracting feature data, quantifying each motion symptom of the Parkinson's patient by means of a trained neural network, and performing comprehensive evaluation based on the quantification result. According to the Parkinson's motion symptom quantitative evaluation method based on the wearable sensing device provided by the invention, each Parkinson's motion symptom of the user can be quantified in a standard manner without accompanying by a professional doctor, and the Parkinson's disease or recovery condition of the user can be comprehensively evaluated; therefore, the Parkinson's disease can be monitored by a user at home in daily life. Meanwhile, the system device provided by the method is simple in principle, convenient to use, high in safety, excellent in real-time performance, high in precision and wide in application range.

The invention discloses an application of rotigotine microspheres in preparation of a medicine for treating inflammatory pain. Rotigotine is a dopamine receptor agonist, and the long-acting sustained-release microsphere can obviously prolong the recession incubation period of the rat posterior claw to thermal stimulation and mechanical stimulation after carrageenan inflammation; the rotigotine microsphere is capable of inhibiting the expression of inflammatory tissue PGE2 and proving that the rotigotine microsphere has an analgesic effect on inflammatory pain, can be used for treating exercisesymptoms of Parkinson's disease and treating the pain of the Parkinson's disease or accompanied diseases, and the analgesic effect can be maintained for 4 days after one-time administration.

The invention relates to the field of new application of medicines, in particular to application of anisodine hydrobromide in treatment of Parkinson's disease. The Parkinson's disease (PD) is a common neurodegenerative disease, the motion symptoms of the PD are acute or static tremor, motion retardation, myotonia, posture balance disorder and the like, at present, the Parkinson's disease is clinically treated mainly by drugs such as levodopa and dopamine, but drug resistance appears along with the prolonging of medication time, and the Parkinson's disease is caused by the drug resistance. The treatment effect and rehabilitation are directly influenced. The anisodine hydrobromide can well improve the treatment effect and shorten the treatment time, so that the influence of drug resistance is reduced.

The invention discloses a method for treatment of epilepsy-associated motor symptom and / or cognitive impairment, by co-administering clavulanic acid and valproic acid to an epilepsy subject in need thereof. Clavulanic acid can be administrated in a dosage of 0.016-10 mg / kg / day, while valproic acid can be administrated in a dosage of 0.8-30 mg / kg / day. Moreover, clavulanic acid and valproic acid can be administrated concurrently, sequentially, separately, continuously or intermittently. In addition, clavulanic acid, as well as valproic acid, can be administrated orally or parenterally.

A method of treating a subject for Parkinson's disease comprises administering said subject a phenylisopropylamine in an amount effective to treat said Parkinson's disease. In some embodiments the method is used to treat at least a motor symptom of Parkinson's disease; in some embodiments the method is used to treat at least a non-motor symptom of Parkinson's disease.

The invention provides a medicine composition for treating Parkinson's disease and application of the medicine composition, and further provides a health-care product and food for improving Parkinson's disease symptoms and application of the health-care product and the food. The medicine composition, the health care product and the food can comprehensively improve the exercise and non-exercise symptoms of the Parkinson's disease.

The invention introduces a method of inhibiting abuse potential and psychosis associated with long term use of apomorphine. Apomorphine used for the treatment of motor symptoms in Parkinson's disease produces addiction, and psychosis. The present method shows that apomorphine plus buspirone combination in the ratio of 1:1 will not produce psychosis. The combination will not be addictive too.

The invention discloses a pharmaceutical composition, including clavulanic acid and valproic acid, for treatment of epilepsy seizure and / or for treatment of epilepsy-associated motor symptom and cognitive impairment. The invention also discloses a method treatment of epilepsy seizure and / or for treatment of epilepsy-associated motor symptom and cognitive impairment, by co-administering clavulanic acid and valproic acid to a subject in need thereof.